Free Trial

Canaan Partners XI LLC Has $38.55 Million Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Tyra Biosciences logo with Medical background

Canaan Partners XI LLC cut its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 0.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,144,590 shares of the company's stock after selling 35,267 shares during the quarter. Tyra Biosciences makes up 58.1% of Canaan Partners XI LLC's investment portfolio, making the stock its largest position. Canaan Partners XI LLC owned about 7.81% of Tyra Biosciences worth $38,545,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TYRA. Rhumbline Advisers raised its holdings in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after acquiring an additional 1,027 shares in the last quarter. RA Capital Management L.P. increased its stake in Tyra Biosciences by 2.1% during the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after purchasing an additional 220,681 shares during the last quarter. Deutsche Bank AG grew its position in shares of Tyra Biosciences by 52.0% during the fourth quarter. Deutsche Bank AG now owns 18,909 shares of the company's stock worth $263,000 after acquiring an additional 6,466 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Tyra Biosciences during the fourth quarter worth about $761,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Tyra Biosciences by 283.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 37,981 shares of the company's stock worth $528,000 after acquiring an additional 28,074 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Up 6.3%

Shares of NASDAQ:TYRA traded up $0.61 during trading on Wednesday, reaching $10.26. The stock had a trading volume of 832,093 shares, compared to its average volume of 271,091. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60. The firm has a market capitalization of $544.70 million, a price-to-earnings ratio of -6.37 and a beta of 1.17. The stock has a fifty day simple moving average of $9.25 and a two-hundred day simple moving average of $12.26.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

TYRA has been the subject of several recent research reports. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 target price on the stock. Finally, Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $30.83.

Check Out Our Latest Stock Report on TYRA

Tyra Biosciences Profile

(Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Further Reading

Institutional Ownership by Quarter for Tyra Biosciences (NASDAQ:TYRA)

Should You Invest $1,000 in Tyra Biosciences Right Now?

Before you consider Tyra Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.

While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines